Follow Us:
Login
Register
Logout
My Profile
My Courses
Courses
Series
Specialties
Hematology/Oncology
Primary Care
Neurology
Cardiology
Psychiatric Medicine
Asthma & Allergies
Emergency Medicine
Endocrinology
Pediatrics
Infectious Disease
Pharmacy
Events
COVID-19
Home
» The Impact of Targeted IL-17 Inhibition on the Treatment for Moderate to Severe Plaque Psoriasis
The Impact of Targeted IL-17 Inhibition on the Treatment for Moderate to Severe Plaque Psoriasis
CME: 0.75
December 2, 2021
No Comments
Email
/
Print
/
Reprints
/
|
More
/
Text Size+
Larger
Smaller
[X]
Related Articles
Expert Illustrations & Commentaries Live: The Future of JAK/TYK2 Inhibition in the Treatment of Psoriasis
Â
Source:
https://learning.freecme.com/a/38584P2Azq8
Post a comment to this article
Name
*
E-mail
(will not be displayed)
*
Subject
Comment
*
Report Abusive Comment
Thank you for helping us to improve our forums. Is this comment offensive? Please tell us why.
More